BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kim H, Hong JY, Lee J, Park SH, Park JO, Park YS, Lim HY, Kang WK, Kim KM, Kim ST. Clinical sequencing to assess tumor mutational burden as a useful biomarker to immunotherapy in various solid tumors. Ther Adv Med Oncol 2021;13:1758835921992992. [PMID: 33717226 DOI: 10.1177/1758835921992992] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Sun H, Chen L, Huang R, Pan H, Zuo Y, Zhao R, Xue Y, Song H. Prognostic nutritional index for predicting the clinical outcomes of patients with gastric cancer who received immune checkpoint inhibitors. Front Nutr 2022;9. [DOI: 10.3389/fnut.2022.1038118] [Reference Citation Analysis]
2 Zheng J, Shao M, Yang W, Ren J, Chen X, Yang H. Benefits of combination therapy with immune checkpoint inhibitors and predictive role of tumour mutation burden in hepatocellular carcinoma: A systematic review and meta-analysis. Int Immunopharmacol 2022;112:109244. [PMID: 36126410 DOI: 10.1016/j.intimp.2022.109244] [Reference Citation Analysis]
3 Wu C, Jiang B, Wu Z, Dong L, Sun K, Wu M, Mei J. LOX and Its Methylation Impact Prognosis of Diseases and Correlate with TAM Infiltration in ESCA. Journal of Oncology 2022;2022:1-18. [DOI: 10.1155/2022/5111237] [Reference Citation Analysis]
4 Kim H, Kim R, Jo H, Kim HR, Hong J, Ha SY, Park JO, Kim ST. Expression of PD-L1 as a predictive marker of sensitivity to immune checkpoint inhibitors in patients with advanced biliary tract cancer. Therap Adv Gastroenterol 2022;15:17562848221117638. [PMID: 35992188 DOI: 10.1177/17562848221117638] [Reference Citation Analysis]
5 Wei C, Li M, Lin S, Xiao J, Parameshachari BD. Characterization of Tumor Mutation Burden-Based Gene Signature and Molecular Subtypes to Assist Precision Treatment in Gastric Cancer. BioMed Research International 2022;2022:1-27. [DOI: 10.1155/2022/4006507] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Li Y, Liu Y, Qu Y, Chen X, Qu X, Ye Y, Du X, Cheng Y, Xu M, Zhang H. Case Report: Two Cases of Soft-Tissue Sarcomas: High TMB as a Potential Predictive Biomarker for Anlotinib Combined With Toripalimab Therapy. Front Immunol 2022;13:832593. [DOI: 10.3389/fimmu.2022.832593] [Reference Citation Analysis]
7 Giorgione R, Risaliti M, Bartolini I, Rossi G, Pillozzi S, Muiesan P, Taddei A, Antonuzzo L. The emerging role of immunotherapy in biliary tract cancer: a review of new evidence and predictive biomarkers. Immunotherapy 2022. [PMID: 35382560 DOI: 10.2217/imt-2021-0257] [Reference Citation Analysis]
8 Hyung S, Han B, Jung J, Kim ST, Hong JY, Park SH, Zang DY, Park JO, Park YS, Kim KM, Kang WK, Lee J. Incidence of FGFR2 Amplification and FGFR2 Fusion in Patients with Metastatic Cancer Using Clinical Sequencing. J Oncol 2022;2022:9714570. [PMID: 35342406 DOI: 10.1155/2022/9714570] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Cao J, Yang X, Chen S, Wang J, Fan X, Fu S, Yang L. The predictive efficacy of tumor mutation burden in immunotherapy across multiple cancer types: A meta-analysis and bioinformatics analysis. Transl Oncol 2022;20:101375. [PMID: 35339028 DOI: 10.1016/j.tranon.2022.101375] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
10 Wang Y, Ye W, Tian G, Zhang Y. Identification of a new RNA-binding proteins-based signature for prognostic prediction in gastric cancer. Medicine (Baltimore) 2022;101:e28901. [PMID: 35212295 DOI: 10.1097/MD.0000000000028901] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Lv W, Cheng K, Li X, Feng L, Li H, Li J, Chang C, Cao D. Case Report: Favorable Response and Manageable Toxicity to the Combination of Camrelizumab, Oxaliplatin, and Oral S-1 in a Patient With Advanced Epstein-Barr Virus-Associated Gastric Cancer. Front Oncol 2021;11:759652. [PMID: 35096571 DOI: 10.3389/fonc.2021.759652] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Jin G, Wang C, Jia D, Qian W, Yin C, Wang D, Yang Q, Li T, Zheng A. Next Generation Sequencing Reveals Pathogenic and Actionable Genetic Alterations of Soft Tissue Sarcoma in Chinese Patients: A Single Center Experience. Technol Cancer Res Treat 2021;20:15330338211068964. [PMID: 34939467 DOI: 10.1177/15330338211068964] [Reference Citation Analysis]
13 Fan X, Song J, Fan Y, Li J, Chen Y, Zhu H, Zhang Z. CSMD1 Mutation Related to Immunity Can Be Used as a Marker to Evaluate the Clinical Therapeutic Effect and Prognosis of Patients with Esophageal Cancer. Int J Gen Med 2021;14:8689-710. [PMID: 34849012 DOI: 10.2147/IJGM.S338284] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
14 Kim H, Ahn S, Kim H, Hong JY, Lee J, Park SH, Park JO, Park YS, Lim HY, Kang WK, Kim KM, Kim ST. The prevalence of homologous recombination deficiency (HRD) in various solid tumors and the role of HRD as a single biomarker to immune checkpoint inhibitors. J Cancer Res Clin Oncol 2021. [PMID: 34510272 DOI: 10.1007/s00432-021-03781-6] [Reference Citation Analysis]
15 Shrestha R, Bridle KR, Crawford DHG, Jayachandran A. Immune checkpoint molecules are regulated by transforming growth factor (TGF)-β1-induced epithelial-to-mesenchymal transition in hepatocellular carcinoma. Int J Med Sci 2021;18:2466-79. [PMID: 34104078 DOI: 10.7150/ijms.54239] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]